Expertise in
36
conditions

Dr. Amanda L. Gillespie-Twardy

Hematology Oncology | Hematology | Oncology
Oncology And Hematology Associates Of Southwest Virginia Inc
2013 Jefferson St Sw, 
Roanoke, VA 
Accepting New Patients
Offers Telehealth
Expertise in
36
conditions
Oncology And Hematology Associates Of Southwest Virginia Inc
2013 Jefferson St Sw, 
Roanoke, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amanda Gillespie-Twardy is a Hematologist Oncology specialist and a Hematologist in Roanoke, Virginia. Dr. Gillespie-Twardy is highly rated in 36 conditions, according to our data. Her top areas of expertise are Lung Cancer, Melanoma, Pleuropulmonary Blastoma, Clear Cell Sarcoma, and Bone Marrow Aspiration. Dr. Gillespie-Twardy is currently accepting new patients.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Carilion Medical Center
Carilion Franklin Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
View 1 Less Insurance Carrier -

Locations

ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA INC
2013 Jefferson St Sw, Roanoke, VA 24014

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
View 9 Less Clinical Trials

9 Total Publications

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Journal: Future oncology (London, England)
Published: August 12, 2024
Similar Doctors
Expertise in
34
conditions
Dr. Jerome H. Goldschmidt
Hematology Oncology | Hematology | Oncology
Expertise in
34
conditions
Dr. Jerome H. Goldschmidt
Hematology Oncology | Hematology | Oncology

Oncology And Hematology Associates Of Southwest Virginia Inc

2013 Jefferson St Sw, 
Roanoke, VA 
 (0.1 mi)
540-982-0237
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jerome Goldschmidt is a Hematologist Oncology specialist and a Hematologist in Roanoke, Virginia. Dr. Goldschmidt is highly rated in 34 conditions, according to our data. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Goldschmidt is currently accepting new patients.

Expertise in
37
conditions
Dr. Suzan R. Merten
Hematology Oncology | Oncology | Hematology
Expertise in
37
conditions
Dr. Suzan R. Merten
Hematology Oncology | Oncology | Hematology

Oncology And Hematology Associates Of Southwest Virginia Inc

2013 Jefferson St Sw, Fl 2, 
Roanoke, VA 
 (0.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzan Merten is a Hematologist Oncology specialist and an Oncologist in Roanoke, Virginia. Dr. Merten is highly rated in 37 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Breast Cancer, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Merten is currently accepting new patients.

Expertise in
41
conditions
Dr. Vandana R. Karri
Hematology Oncology | Hematology | Oncology
Expertise in
41
conditions
Dr. Vandana R. Karri
Hematology Oncology | Hematology | Oncology

Lewis Gale Physicians LLC

1802 Braeburn Dr, 
Salem, VA 
 (4.8 mi)
540-772-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vandana Karri is a Hematologist Oncology specialist and a Hematologist in Salem, Virginia. Dr. Karri is highly rated in 41 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Lung Cancer. Dr. Karri is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gillespie-Twardy's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 80 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile